When curing a disease with gene therapy is bad business

MIT Technology Review -

MIT Technology Review—A drug giant turns over its pipeline of miracle drugs to a startup.

Goldman Sachs Warns That Curing Diseases Through Gene Editing Technology Is Bad For Profit Margins. Recent breakthroughs in the field of genetic editing have caused a great deal of debate between proponents of the technology who think it can cure many diseases and alleviate human suffering on a scale never before seen and skeptics of the technology who believe that genetic editing is an instance of man playing God and could have terrible unintended consequences.